Post-Marketing Safety Surveillance for the Adjuvanted Recombinant Zoster Vaccine: Methodology

A diligent, systematic, regular review of aggregate safety data is essential, particularly early after vaccine introduction, as this is when safety signals not identified during clinical development may emerge. In October 2017, the US Centers for Disease Control and Prevention Advisory Committee on...

Descripción completa

Detalles Bibliográficos
Autores principales: Tavares-Da-Silva, Fernanda, Mahaux, Olivia, Van Holle, Lionel, Haguinet, François, Seifert, Harry, Stegmann, Jens-Ulrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Leading Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7686206/
https://www.ncbi.nlm.nih.gov/pubmed/32862397
http://dx.doi.org/10.1007/s40264-020-00989-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7686206/
https://www.ncbi.nlm.nih.gov/pubmed/32862397
http://dx.doi.org/10.1007/s40264-020-00989-2

Ejemplares similares